Discover the company that Forbes is calling a *Promising Stock* in a sickly biotech market!
** Nasdaq: VRPX **
OVERVIEW
Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) is combatting the expensive and deadly opioid epidemic by developing non-addictive products for pain management using its proprietary technologies to optimize and target drug delivery.
The company is seeking FDA approval in three multi-billion-dollar markets. Probudur for postoperative pain, Envelta for severe pain including post cancer pain, and NobrXiol for the management of rare pediatric epilepsy and potential orphan diseases.
If approved, these product candidates will fundamentally change what prescribers recommend managing their patients' severe pain, Epilepsy, and other CNS disorders in the future.
Understanding the Opioid Overdose Epidemic
What to know:
The number of opioid-involved deaths has increased substantially since 1999.
There have been three distinct waves of increases in opioid overdose deaths over the last 25 years, with each wave driven by different types of opioids.
The U.S. Congress Joint Economic Committee (JEC)—led by Chairman Don Beyer (D-VA)—released a new analysis that finds the opioid epidemic cost the United States a record of nearly $1.5 trillion in 2020. This is up a staggering 37% from 2017, when the CDC last measured the cost.
A Competitive Edge with Probudur
Virpax's pain management drug candidate and lead product candidate, Probudur, has what's known as "stickiness," the company says, meaning that in preclinical studies it lasts longer than rivals' products.
Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain. In preclinical studies, Probudur has shown long duration pain control for at least 96 hours, with a rat incisional model demonstrating analgesia for up to five days and in vitro studies demonstrating a slow release of bupivacaine that lasted for up to six days.
POTENTIAL BENEFITS
Animal studies demonstrated 96 hours of local anesthetic activity at wound site
May eliminate the need for opioids after surgery!
May reduce associated costs and length of hospital stay
Produced no evidence of motor or sensory nerve damage at a dose that was 10 times higher than free bupivacaine in animal studies
NEW DRUG APPLICATION (NDA)
As a result of the company's PreIND review, the FDA has indicated that it is reasonable for Virpax to pursue an accelerated 505(b)(2) New Drug Application for Probudur.
Study Results
A minipig Dose Range Finding ("DRF") study for Probudur was conducted to evaluate the tolerance of Probudur in an incisional wound healing model in minipigs. Probudur was injected locally into the tissue surrounding the incision area. All of the minipigs demonstrated positive tolerance to Probudur and no adverse effects were noted. The development program for Probudur continues to support the Company's belief that Probudur has the potential to provide both immediate and sustained pain relief at the incisional area.
"These positive study results in our pharmacokinetics and safety studies for Probudur and continue to demonstrate both immediate relief as well as sustained relief at the wound site," stated Jatinder Dhaliwal, Chief Executive Officer of Virpax. "The completion of these studies brings us another step closer to filing our Investigational New Drug Application (IND) for Probudur."
Military grants and CRADA awards for VRPX's Rx product candidates
US Army Institute of Surgical Research (USAISR) Awarded 5/05/2022 Extended 10/09/2023
National Center for Advancing Translational Sciences (NCATS) Awarded 8/31/2020
National Institute of Neurological Disorders and Stroke (NINDS) Awarded 4/19/2023
Targeting the Brain to Manage CNS Disorders
The company's patented Molecular Envelope Technology (MET) platform is being used to grow our Central Nervous System (CNS) disorder pipeline. The current CNS product indications include Post Traumatic Stress Disorder (PES200), and Rare Pediatric Epilepsy (NobrXiol).
MET will significantly improve our drug delivery process characteristics by directly targeting the brain to manage CNS disorder symptoms.
Virpax is collaborating with the National Advisory Neurological Disorders and Stroke Council (NINDS) and Epilepsy Therapy Screening Program (ETSP) to begin preclinical development of NobrXiol for the treatment of pediatric epilepsy. The mission of ETSP is to identify novel agents that may address unmet medical needs in epilepsy.
What is Forbes Saying?
"Few investors have the scientific background to assess whether a fledgling biotech firm has the stuff to go on to glory. But some signals point to which could be the most promising, such as grants they have received and high-level outside interest. An example of that is Virpax Pharmaceuticals, which focuses on pain management—and does so without the addictive aspect of opioids. The company has received grants from the National Institutes of Health and the Pentagon. The U.S. Army is studying the use of one of its drugs for battlefield wounds and other injuries."
In Summary
VRPX is addressing the opioid crisis and lucrative markets by delivering innovative and safer pain management solutions. To see all of the company's products, click HERE.
Biopharma companies are tied closely to study data and approval decisions from the U.S. Food and Drug Administration or other drug regulators.
Keep a close eye on VRPX's news for any potential progress with the FDA! Promising news could serve as a tremendous catalyst for growth potential.
Disclaimer:
We are engaged in the business of advertising and promoting companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Trading Wire nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisers, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed on Trading Wire. It is possible that a viewer's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. Trading Wire makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website.
Some of the content on this website contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which may be beyond a company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. It is hereby noted that forward-looking statements contained herein may include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward-looking statements or announcements mentioned on this website or the websites contained within. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company's filings with the Securities and Exchange Commission. However, a company's past performance does not guarantee future results.
Generally, the information regarding a company profiled or discussed on this website is provided from public sources tradingwire.com makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained through our website or in communications originating from our website. Viewers should use the information provided by us regarding the profiled companies as a starting point for additional independent research on the companies profiled or discussed in order to allow the viewer to form his or her own opinion regarding investing in the securities of such companies. Factual statements, or the similar, made by the profiled companies are made as of the date stated and are subject to change without notice and Trading Wire has no obligation to update any of the information provided. Trading Wire, its owners, officers, directors, contractors and employees are not responsible for errors and omissions.
From time to time certain content on this website is written and published by our employees or third parties. In addition to information about our profiled companies, from time to time, our website will contain the symbols of companies and/or news feeds about companies that are not being profiled by us but are merely illustrative of certain activity in the micro cap or penny stock market that we are highlighting. Viewers are advised that all analysis reports and news feeds are issued solely for informational purposes. Any opinions expressed are subject to change without notice. It is also possible that one or more of the companies discussed or profiled on this website may not have approved certain or any statements within the website. Trading Wire encourages viewers to supplement the information obtained from this website with independent research and other professional advice. The content on this website is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Third Party Web Sites and Other Information This website may provide hyperlinks to third party websites or access to third party content.Trading Wire, its owners, officers, directors, contractors and employees are not responsible for errors and omissions nor does Trading Wire control, endorse, or guarantee any content found in such sites. Trading Wire does not control, endorse, or guarantee content found in such sites. By accessing, viewing, or using the website or communications originating from the website, you agree that Trading Wire, its owners, officers, directors, contractors and employees, are not responsible for any content, associated links, resources, or services associated with a third party website. You further agree that Trading Wire, its owners, officers, directors, contractors and employees shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only. Trading Wire uses third parties to disseminate information to subscribers. Although we take precautions to prevent others from obtaining our subscriber list, there is a risk that our subscriber list, through no wrong doing on our part, could end up in the hands of an unauthorized party and that subscribers will receive communications from unauthorized third parties. We encourage viewers to invest carefully and read the investor issuer information available at the web sites of the United States Securities and Exchange Commission (SEC). The SEC has launched an investor-focused website to help you invest wisely and avoid fraud at www.investor.gov and filings made by public companies can be viewed at www.sec.gov and/or the Financial Industry Regulatory Authority (FINRA) at: www.finra.org. In addition, FINRA has published information at its website on how to invest carefully at www.finra.org/Investors/index.htm.
Income Disclaimer
Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your future results or success, and are not responsible for your actions.
Income Disclaimer
Testimonials and examples used here are exceptional results which may not apply to the average purchaser. They are not intended to represent or guarantee that anyone will achieve the same or similar results through our service. The use of our information should be based on your own due diligence, and you agree that our company is not liable for any success or failure of your business that is directly or indirectly related to the use of our information. As with any business, your results may vary, and will be based on your individual capacity, business experience and expertise. There are no guarantees concerning the level of success you may experience. Income statements made by our customers are only estimates of what they have earned; there is no guarantee that you will make these levels of income. When using our information you accept the risk that these earnings and income statements differ by individual. There is no assurance that examples of past earnings can be duplicated in the future. There are unknown risks in business and on the internet that we cannot anticipate which can reduce results. We therefore cannot guarantee your
future results or success, and are not responsible for your actions.
Trading Wire has been retained by Virpax Pharmaceuticals (NASDAQ:VRPX) to perform promotional and advertising services for a limited time with respect to the company we are profiling or discussing on this website and in exchange for such services has received cash compensation from Virpax Pharmaceuticals (NASDAQ:VRPX) . Questions regarding this website may be sent to editor@tradingwire.com
Trading Wire has received a payment of $300,000.00 from Virpax Pharmaceuticals (NASDAQ:VRPX) for the marketing of AVirpax Pharmaceuticals (NASDAQ:VRPX)) . which services include the issuance of this release and other opinions that we release concerning of Virpax Pharmaceuticals (NASDAQ:VRPX) Trading Wire has not investigated the background ofVirpax Pharmaceuticals (NASDAQ:VRPX) . Anyone viewing this newsletter should assume Virpax Pharmaceuticals (NASDAQ:VRPX) or affiliates of Virpax Pharmaceuticals (NASDAQ:VRPX)own shares of the Virpax Pharmaceuticals (NASDAQ:VRPX) which they plan to liquidate, and further understand that the liquidation of those shares may or may not negatively impact the share price. Trading Wire has received this amount as a production budget for advertising efforts and will retain amounts over and above the cost of production, copywriting services, mailing and other distribution expenses as a fee for our services. As such, our opinion is neither unbiased nor independent, and you should consider that when evaluating our statements regarding Virpax Pharmaceuticals (NASDAQ:VRPX)
